ews-fli1

TK216 is a potent inhibitor of E26 transformation-specific (ETS) with anticancer activity.

NSC635437 acts as an inhibitor of the EWS-FLI1 oncoprotein in Ewing's sarcoma.

EB-TCIP (BAK-04-212) is a bivalent molecule composed of AP1867 and BI-3812. It facilitates the reversible formation of a ternary complex between FKBPF36V and BCL6BTB, thereby recruiting FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, rapidly inducing expression of BCL6 target genes such as SOCS2 and CXCL11. EWS/FLI1 is a fusion transcription factor found in Ewing sarcoma. EB-TCIP is applicable for studying transcriptional dysregulation in cancer.

Fli-1-IN-1 (compound 21) fumarate is an FLI1-targeting agent that binds directly to and inhibits the interaction of the EWS-FLI1 protein. Since EWS-FLI1 interacts with RNA helicase A, Fli-1-IN-1 fumarate's inhibition of EWS-FLI1 suggests potential anticancer properties.

YK 4-279, an inhibitor of RNA Helicase A (RHA), binds to the oncogenic transciption factor EWS-FLI1.

Fli-1-IN-1 (compound 21) serves as a FLI1 inhibitor by binding directly to the EWS-FLI1 protein, disrupting its interaction with RNA helicase A. This inhibition holds potential anticancer properties [1].

TK-216 D4 is a deuterated isomer of TK-216. TK216 is an orally active E26 transcription factor (ETS) inhibitor. TK216 binds to the EWS-FLI1 fusion protein, blocking its protein-protein interaction with RNA helicase A (RHA/DHX9) and inhibiting ETS transcription factor-mediated oncogene transcription. TK216 is used in cancer research.